Arvinas Biopharmaceuticals, Pfizer, and Genentech have all investigated the application of PROTACs in neurodegenerative diseases, particularly in targeting pathological proteins such as tau and α-synuclein in AD and PD. This evidence concerns the gene MAPT and neurodegenerative disease.